GlassScriptPhysician profile
Megan Linders
NPI 1336704253
$750.34
in general payments reported to CMS, 2019-2025
18 companies · $671 in 2025
The $671 reported for 2025 was more than what 79% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $20.98 · 2023: $23.81 · 2024: $34.97 · 2025: $671.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $729.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $729.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $189.36 | 2023-2025 | |
| Novo Nordisk INC | $72.09 | 2025 | Wegovy |
| Glaxosmithkline, LLC. | $68.43 | 2025 | Nucala, Trelegy Ellipta |
| Amgen INC. | $41.41 | 2025 | Evenity |
| Astrazeneca Pharmaceuticals LP | $38.33 | 2025 | Tezspire |
| Philips North America LLC | $36.85 | 2025 | Extended Holter |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $34.97 | 2024 | Lifevest |
| Lilly USA, LLC | $33.81 | 2025 | Mounjaro |
| Teva Pharmaceuticals USA, INC. | $32.24 | 2025 | Ajovy |
| Exact Sciences Corporation | $31.57 | 2025 | Cologuard Collection Kit |
| Genzyme Corporation | $30.26 | 2025 | |
| Edwards Lifesciences Corporation | $26.85 | 2025 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $21.72 | 2025 | Xifaxan |
| Takeda Pharmaceuticals U.S.A., INC. | $20.98 | 2022 | |
| Boston Scientific Corporation | $20.92 | 2025 | Ams 700 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $18.76 | 2025 | Winrevair |
| Dexcom, INC. | $17.76 | 2025 | Dexcom G6 Transmitter |
| Verona Pharma, INC. | $14.03 | 2025 | Ohtuvayre |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Megan Linders listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.